Goldman Sachs Alternatives, an investment company, led a $95m Series C round in Ajax Therapeutics, a biotechnology company, with participation from Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72, EcoR1 Capital, Boxer Capital, Schrödinger, Inc. and Inning One Ventures. “We’re pleased to have attracted this level of support from such distinguished life sciences investors and biopharmaceutical companies in addition to our existing investor syndicate. We are now well positioned to bring much needed innovation to the field of JAK inhibitors for the treatment of MPNs and look forward to advancing AJ1‑11095 into the clinic for myelofibrosis later this year,” Martin Vogelbaum, Ajax Therapeutics Co-Founder and CEO.